metformin has been researched along with ethambutol in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gründemann, D; Pan, X; Sweet, DH; Wang, L | 1 |
Ali, M; Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI | 1 |
Balganesh, T; Bhavani, PK; Gomathy, SN; Guleria, R; Jawahar, SM; Kumar, H; Natrajan, M; Padmapriyadarsini, C; Ponnuraja, C; Singh, M; Swaminathan, S | 1 |
1 review(s) available for metformin and ethambutol
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for metformin and ethambutol
Article | Year |
---|---|
Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Topics: Adult; Antibiotics, Antitubercular; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; India; Isoniazid; Metformin; Multicenter Studies as Topic; Mycobacterium tuberculosis; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary | 2019 |
7 other study(ies) available for metformin and ethambutol
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.
Topics: Animals; Antitubercular Agents; Biological Transport; CHO Cells; Cricetulus; Drug Interactions; Enterocytes; Ethambutol; Hepatocytes; Humans; Lamivudine; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 1 | 2013 |
Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study.
Topics: Adult; Antitubercular Agents; Autophagy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ethambutol; Humans; Hypoglycemic Agents; Insulin; Interferon-gamma; Interleukin-10; Isoniazid; Leukocytes, Mononuclear; Metformin; Microtubule-Associated Proteins; Middle Aged; Pyrazinamide; Rifampin; Sputum; Superoxide Dismutase; Tuberculosis | 2019 |